89Bio IncNASDAQ:ETNB
- LAST PRICE7.2950
- TODAY'S CHANGE (%)-0.1050 (-1.4189%)
- Bid / Lots7.2900/ 2
- Ask / Lots7.3000/ 3
- Open / Previous Close7.3600 / 7.4000
- Day Range
- 52 Week Range
- Volume443,852
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ETNB |
|---|---|---|
| 09:32 ET | 4127 | 7.365 |
| 09:34 ET | 13558 | 7.21 |
| 09:36 ET | 2685 | 7.135 |
| 09:38 ET | 1886 | 7.15 |
| 09:39 ET | 52694 | 7.145 |
| 09:41 ET | 600 | 7.145 |
| 09:43 ET | 2050 | 7.15 |
| 09:45 ET | 900 | 7.175 |
| 09:48 ET | 2544 | 7.16 |
| 09:50 ET | 1748 | 7.19 |
| 09:52 ET | 1156 | 7.175 |
| 09:54 ET | 102796 | 7.21 |
| 09:56 ET | 3567 | 7.26 |
| 09:59 ET | 11609 | 7.18 |
| 10:01 ET | 1779 | 7.22 |
| 10:03 ET | 10205 | 7.21 |
| 10:06 ET | 6948 | 7.2153 |
| 10:08 ET | 1060 | 7.1411 |
| 10:10 ET | 2313 | 7.12 |
| 10:12 ET | 3854 | 7.11 |
| 10:14 ET | 3732 | 7.1 |
| 10:15 ET | 42380 | 7.145 |
| 10:17 ET | 10753 | 7.15 |
| 10:19 ET | 1970 | 7.13 |
| 10:21 ET | 3340 | 7.16 |
| 10:24 ET | 2783 | 7.22 |
| 10:26 ET | 1367 | 7.195 |
| 10:28 ET | 700 | 7.14 |
| 10:30 ET | 1300 | 7.15 |
| 10:32 ET | 2403 | 7.15 |
| 10:33 ET | 1361 | 7.15 |
| 10:35 ET | 2193 | 7.175 |
| 10:37 ET | 500 | 7.21 |
| 10:39 ET | 200 | 7.21 |
| 10:42 ET | 2740 | 7.2 |
| 10:44 ET | 3838 | 7.215 |
| 10:48 ET | 850 | 7.2 |
| 10:50 ET | 1268 | 7.17 |
| 10:51 ET | 100 | 7.175 |
| 10:53 ET | 500 | 7.16 |
| 10:55 ET | 1489 | 7.16 |
| 10:57 ET | 2968 | 7.165 |
| 11:00 ET | 2840 | 7.19 |
| 11:04 ET | 3163 | 7.21 |
| 11:06 ET | 1563 | 7.19 |
| 11:08 ET | 1984 | 7.21 |
| 11:09 ET | 655 | 7.19 |
| 11:11 ET | 100 | 7.18 |
| 11:13 ET | 350 | 7.185 |
| 11:15 ET | 751 | 7.18 |
| 11:18 ET | 1015 | 7.17 |
| 11:20 ET | 100 | 7.165 |
| 11:22 ET | 300 | 7.17 |
| 11:24 ET | 1126 | 7.219 |
| 11:26 ET | 1890 | 7.185 |
| 11:27 ET | 100 | 7.2 |
| 11:29 ET | 700 | 7.21 |
| 11:31 ET | 885 | 7.22 |
| 11:33 ET | 752 | 7.215 |
| 11:36 ET | 314 | 7.22 |
| 11:38 ET | 600 | 7.22 |
| 11:40 ET | 775 | 7.23 |
| 11:42 ET | 400 | 7.23 |
| 11:44 ET | 200 | 7.245 |
| 11:45 ET | 1567 | 7.26 |
| 11:47 ET | 500 | 7.25 |
| 11:49 ET | 400 | 7.24 |
| 11:51 ET | 500 | 7.2357 |
| 11:54 ET | 800 | 7.26 |
| 11:56 ET | 702 | 7.24 |
| 11:58 ET | 671 | 7.23 |
| 12:00 ET | 664 | 7.24 |
| 12:02 ET | 500 | 7.24 |
| 12:03 ET | 2000 | 7.25 |
| 12:05 ET | 200 | 7.27 |
| 12:07 ET | 300 | 7.265 |
| 12:09 ET | 1313 | 7.25 |
| 12:12 ET | 800 | 7.26 |
| 12:14 ET | 2687 | 7.295 |
| 12:16 ET | 785 | 7.29 |
| 12:18 ET | 300 | 7.295 |
| 12:20 ET | 850 | 7.3 |
| 12:21 ET | 300 | 7.29 |
| 12:23 ET | 1798 | 7.31 |
| 12:25 ET | 820 | 7.295 |
| 12:27 ET | 200 | 7.3 |
| 12:30 ET | 842 | 7.31 |
| 12:32 ET | 200 | 7.315 |
| 12:34 ET | 618 | 7.3 |
| 12:36 ET | 843 | 7.32 |
| 12:38 ET | 716 | 7.32 |
| 12:39 ET | 700 | 7.31 |
| 12:41 ET | 453 | 7.29 |
| 12:43 ET | 3013 | 7.29 |
| 12:45 ET | 200 | 7.3 |
| 12:48 ET | 800 | 7.29 |
| 12:50 ET | 600 | 7.27 |
| 12:52 ET | 789 | 7.27 |
| 12:54 ET | 854 | 7.28 |
| 12:56 ET | 558 | 7.3 |
| 12:57 ET | 100 | 7.29 |
| 01:01 ET | 300 | 7.31 |
| 01:03 ET | 100 | 7.3 |
| 01:06 ET | 100 | 7.27 |
| 01:08 ET | 400 | 7.23 |
| 01:10 ET | 600 | 7.25 |
| 01:14 ET | 205 | 7.23 |
| 01:15 ET | 308 | 7.23 |
| 01:19 ET | 400 | 7.22 |
| 01:21 ET | 340 | 7.22 |
| 01:24 ET | 500 | 7.23 |
| 01:26 ET | 684 | 7.23 |
| 01:28 ET | 512 | 7.24 |
| 01:30 ET | 894 | 7.24 |
| 01:32 ET | 597 | 7.24 |
| 01:33 ET | 600 | 7.25 |
| 01:35 ET | 300 | 7.26 |
| 01:37 ET | 870 | 7.25 |
| 01:39 ET | 300 | 7.26 |
| 01:42 ET | 100 | 7.25 |
| 01:44 ET | 100 | 7.24 |
| 01:46 ET | 849 | 7.26 |
| 01:48 ET | 100 | 7.25 |
| 01:53 ET | 600 | 7.26 |
| 01:57 ET | 1643 | 7.27 |
| 02:00 ET | 200 | 7.28 |
| 02:02 ET | 100 | 7.29 |
| 02:04 ET | 200 | 7.29 |
| 02:06 ET | 100 | 7.295 |
Yesterday
Sep 20, 2024
DJ 89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald, from 12:24PM ET on Friday Sep 20, 2024 by Dow Jones
12:24PM ET on Friday Sep 20, 2024 by Dow Jones
Sep 19, 2024
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:03PM ET on Thursday Sep 19, 2024 by Dow Jones
4:03PM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 16, 2024
Press Release: 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, from 4:05PM ET on Monday Sep 16, 2024 by Dow Jones
4:05PM ET on Monday Sep 16, 2024 by Dow Jones89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, from 4:05PM ET on Monday Sep 16, 2024 by Dow Jones
4:05PM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
89Bio Inc | 783.7M | -3.7x | --- |
Arrivent Biopharma Inc | 789.3M | -9.5x | --- |
Erasca Inc | 771.2M | -2.8x | --- |
Nuvation Bio Inc | 766.6M | -1.1x | --- |
Rapport Therapeutics Inc | 749.1M | -11.5x | --- |
Replimune Group Inc | 748.8M | -3.5x | --- |
Company Information
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
Contact Information
- Headquarters
- 142 Sansome Street, Second FloorSan Francisco, CA, United States 94104
- Phone
- 415-432-9270
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board of Director
- Steven Altschuler
- Chief Executive Officer, Director
- Rohan Palekar
- Chief Financial Officer
- Ryan Martins
- Chief Operating Officer
- Francis Sarena
- Chief Technical Operations Officer and Head of Quality
- Quoc Le-Nguyen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $783.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 105.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-1.97 |
Book Value | $5.75 |
P/E Ratio | -3.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
